The clearance is a step forward in AstraZeneca and Daiichi Sankyo’s plan to position antibody-drug conjugates like Enhertu ...
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.
The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...
New approval brings the medicine to an earlier treatment setting and a broader patient population.
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...
Hosted on MSN1d
Could the FDA's recently approved Pap smear alternative reduce racial disparities in cervical cancer deaths?Northwell Health partnered with Stacker to explore how a new Pap smear alternative may help prevent deaths from cervical ...
The FDA revokes FD&C Red No. 3 authorization due to cancer concerns under the Delaney Clause, impacting food and drug ...
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
The company is also seeking to expand use of the drug to other cancers. Last week, the FDA accepted an application seeking approval of the ADC for EGFR-mutated non-small cell lung cancer.
On January 17, 2025, the Food and Drug Administration (FDA ... This approval marks a significant advancement in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor ...
Datroway has been approved for unresectable or metastatic HR+, HER2- breast cancer after endocrine therapy and chemotherapy. The Food and Drug Administration (FDA) has approved Datroway (datopotamab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback